Pendopharm has obtained the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat, an on-demand investigational treatment for hereditary angioedema (HAE), in Canada under a licensing agreement with Kalvista Pharmaceuticals, the developer of the therapy. “We look forward to collaborating with Pendopharm, whose deep…
Oral deucrictibant continued to control swelling attacks as a preventative therapy and rapidly stop swelling attacks as an on-demand treatment for hereditary angioedema (HAE), according to new data from the open-label extension portions of two clinical trials. All open-label extension participants said that preventive deucrictibant controlled their HAE…
Kalvista Pharmaceuticals’ sebetralstat, an oral on-demand treatment for hereditary angioedema (HAE), rapidly stopped the progression of swelling attacks, according to interim data from a two-year open-label extension study. It was also effective against attacks involving the larynx (voice box) and abdomen, as well as those rated as severe or…
The U.S. Food and Drug Administration (FDA) has accepted Biocryst Pharmaceuticals’ application to approve an oral granule formulation of Orladeyo (berotralstat) for children with hereditary angioedema (HAE) as young as 2. The FDA granted the application priority review, which shortens the process from the standard 10 months…
Andembry (garadacimab), a first-in-class treatment to prevent swelling attacks in people with hereditary angioedema (HAE), ages 12 and older, is now available in Japan. The treatment was approved by Japan’s Ministry of Health, Labour and Welfare in February, Andembry is the first prophylactic (preventive) therapy in Japan that…
Deucrictibant, an oral therapy being developed for bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema, has been granted orphan drug status in the European Union. This designation, granted by the European Commission, intends to back the development of therapies to diagnose, prevent, or treat rare…
Throughout 2024, Angioedema News brought our readers all the latest news and updates on clinical research and scientific advances related to the rare disease. Here are this year’s top 10 most-read articles on angioedema — many related to the prevention and treatment of swelling, the hallmark of the…
Rare connective tissue diseases are more common among people with hereditary angioedema (HAE) than in the general population, according to the results of a new Italian study the researchers say is the first to seek to better understand disease prevalence among HAE patients. Among the diseases investigated — which…
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking the approval of donidalorsen as a preventive treatment for swelling attacks in adults and children, ages 12 and older, with hereditary angioedema (HAE). According to Ionis Pharmaceuticals, the company developing the therapy, the…
A new mutation in the SERPING1 gene was identified as the cause of hereditary angioedema (HAE) in several members of a Han Chinese family, a study reports. Blood tests revealed varied levels of C1-INH, the protein encoded by the SERPING1 gene and used to help diagnose the condition, in affected…
Get regular updates to your inbox.
